Company press releases
Released | Company | Title | Industry | Topic |
---|---|---|---|---|
03 May 2023 07:00 CEST |
TARGOVAX | Circio: circRNA poster to be presented at the ASGCT Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
28 Apr 2023 08:58 CEST |
TARGOVAX | Targovax ASA - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
19 Apr 2023 20:32 CEST |
TARGOVAX | Targovax to rebrand as Circio, an innovator in next generation circular RNA therapeutics | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
19 Apr 2023 20:32 CEST |
TARGOVAX | Targovax skifter navn til Circio og styrker satsingen på sirkulært RNA | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
13 Apr 2023 23:36 CEST |
TARGOVAX | Targovax ASA: Annual Report 2022 | 20103010 Biotechnology | Annual financial and audit Reports |
13 Apr 2023 12:01 CEST |
TARGOVAX | Targovax ASA: Registration of share capital increase following conversion of convertible bonds | 20103010 Biotechnology | Total number of voting rights and capital |
13 Apr 2023 09:54 CEST |
TARGOVAX | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
30 Mar 2023 11:11 CEST |
TARGOVAX | Targovax ASA: Requested Conversion of Convertible Bonds | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
15 Mar 2023 13:43 CET |
TARGOVAX | Targovax ASA: circRNA poster to be presented at the AACR Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
14 Mar 2023 08:28 CET |
TARGOVAX | Targovax: First patient dosed with TG01 in the USA | 20103010 Biotechnology | Non-regulatory press releases |
09 Mar 2023 20:46 CET |
TARGOVAX | Targovax ASA - First Tranche of Convertible Bonds | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
09 Mar 2023 10:55 CET |
TARGOVAX | Targovax ASA: Minutes from the Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
07 Mar 2023 20:42 CET |
TARGOVAX | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
07 Mar 2023 20:42 CET |
TARGOVAX | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
07 Mar 2023 17:49 CET |
TARGOVAX | Targovax prioriterer utvikling av sirkulær RNA plattform | 20103010 Biotechnology | Innsideinformasjon |
07 Mar 2023 17:49 CET |
TARGOVAX | Targovax to prioritize resources on unlocking the potential of its circRNA platform | 20103010 Biotechnology | Inside information |
06 Mar 2023 17:44 CET |
TARGOVAX | Targovax ASA - Additional information prior to the Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
06 Mar 2023 15:33 CET |
TARGOVAX | Targovax ASA: Registration of share capital increase following settlement of restricted stock units | 20103010 Biotechnology | Total number of voting rights and capital |
02 Mar 2023 13:25 CET |
TARGOVAX | Targovax ASA: Mandatory notification of trade by primary insiders pertaining to RSUs | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
02 Mar 2023 13:15 CET |
TARGOVAX | Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
01 Mar 2023 07:00 CET |
TARGOVAX | Targovax ASA - Additional information prior to the Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
23 Feb 2023 11:50 CET |
TARGOVAX | Targovax invites to Q&A webcast regarding convertible bond financing | 20103010 Biotechnology | Non-regulatory press releases |
20 Feb 2023 08:05 CET |
TARGOVAX | Disclosure in Targovax ASA | 20103010 Biotechnology | Major shareholding notifications |
16 Feb 2023 17:49 CET |
TARGOVAX | Targovax ASA - Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
16 Feb 2023 07:00 CET |
TARGOVAX | Targovax ASA: Fourth quarter 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
16 Feb 2023 06:55 CET |
TARGOVAX | Targovax announces financing of up to NOK 300m over three years to advance its clinical cancer programs & pre-clinical circular RNA platform | 20103010 Biotechnology | Inside information |
16 Feb 2023 06:55 CET |
TARGOVAX | Targovax annonserer finansiering på inntil 300 millioner til utvikling av kreftmedisin og ny sirkulær RNA plattform | 20103010 Biotechnology | Innsideinformasjon |
08 Feb 2023 07:00 CET |
TARGOVAX | Targovax ASA: Invitation to Targovax's fourth quarter 2022 presentation, Thursday 16 February | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
22 Dec 2022 07:00 CET |
TARGOVAX | Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed | 20103010 Biotechnology | Non-regulatory press releases |
20 Dec 2022 22:14 CET |
TARGOVAX | Targovax ASA issues options to employees | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
15 Dec 2022 07:00 CET |
TARGOVAX | Targovax starter samarbeid med Agenus for å teste TG som behandling mot bukspyttkjertelkreft | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
15 Dec 2022 07:00 CET |
TARGOVAX | Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer | 20103010 Biotechnology | Non-regulatory press releases |
07 Dec 2022 11:49 CET |
TARGOVAX | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
07 Dec 2022 11:49 CET |
TARGOVAX | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
07 Dec 2022 07:00 CET |
TARGOVAX | Targovax to present and attend at upcoming conferences | 20103010 Biotechnology | Non-regulatory press releases |
10 Nov 2022 07:00 CET |
TARGOVAX | Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement | 20103010 Biotechnology | Non-regulatory press releases |
03 Nov 2022 07:00 CET |
TARGOVAX | Targovax ASA: Third quarter 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
26 Oct 2022 07:00 CEST |
TARGOVAX | Invitation to Targovax's third quarter 2022 presentation, Thursday 3 November | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
20 Oct 2022 08:20 CEST |
TARGOVAX | The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research - with updated publication info | 20103010 Biotechnology | Non-regulatory press releases |
20 Oct 2022 07:00 CEST |
TARGOVAX | The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research | 20103010 Biotechnology | Non-regulatory press releases |
05 Oct 2022 14:05 CEST |
TARGOVAX | The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting | 20103010 Biotechnology | Non-regulatory press releases |
27 Sep 2022 07:00 CEST |
TARGOVAX | Targovax' studie i føflekkreft har blitt godkjent for oppstart av amerikanske FDA | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
27 Sep 2022 07:00 CEST |
TARGOVAX | Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA | 20103010 Biotechnology | Non-regulatory press releases |
26 Sep 2022 14:00 CEST |
TARGOVAX | Reminder: Targovax to host Investor Event 27 September | 20103010 Biotechnology | Non-regulatory press releases |
26 Sep 2022 14:00 CEST |
TARGOVAX | Påminnelse: Targovax arrangerer investormøte 27. september | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
19 Sep 2022 11:54 CEST |
TARGOVAX | Targovax arrangerer investormøte: Møt ledelsen 27. september | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
19 Sep 2022 11:54 CEST |
TARGOVAX | Targovax to host Investor Event: Meet the Management on 27 September | 20103010 Biotechnology | Non-regulatory press releases |
12 Sep 2022 07:00 CEST |
TARGOVAX | Targovax to present at upcoming conferences | 20103010 Biotechnology | Non-regulatory press releases |
18 Aug 2022 07:00 CEST |
TARGOVAX | Targovax ASA: Second quarter and first half year 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
11 Aug 2022 07:00 CEST |
TARGOVAX | Targovax ASA: Invitation to Targovax's second quarter and first half 2022 presentation, Thursday 18 August | 20103010 Biotechnology | Non-regulatory press releases |